News Briefing channel feed

Ax­some clears Phase 3 in nar­colep­sy; Nkar­ta eyes $240M raise

Last year

In­tel­lia ex­its he­mo­phil­ia B pact with Re­gen­eron; Sang­amo tar­gets $24M raise

Last year

In­nate ends Ph1b in pe­riph­er­al T cell lym­phoma; Lay­offs at NextCure

Last year

Ab­b­Vie inks deal with Parvus; Sofinno­va in­vests in Cure51

Last year

Madri­gal's $600M of­fer­ing; PureTech to re­turn $100M to share­hold­ers

Last year

Blue­bird's $175M loan; Spyre re­veals sec­ond pri­vate place­ment

Last year

Bio­theus builds on ADC pact with Han­soh; No­var­tis ex­pands in Sin­ga­pore; Astel­las leaves Carte­sian deal

Last year

OcuTer­ra’s di­a­bet­ic retinopa­thy drug fails PhII; Bet­ter Ther­a­peu­tics to shut down

Last year

Takeda's PhII meza­gi­ta­m­ab da­ta; Apogee's $483M raise; Gal­der­ma's IPO

Last year

Reg­u­lus rais­es $100M; Can­cer com­pa­ny files to go pub­lic

Last year

Lex­eo brings in $95M; FDA lifts hold on Nurix can­cer tri­al

Last year

In­ven­ti­va restarts PhI­II screen­ing for MASH tri­al; CD­MO an­nounces small pub­lic of­fer­ing

Last year

Ul­ti­movac­s' melanoma vac­cine fails in PhII; Re­genxbio’s $140M of­fer­ing

Last year

Apogee's $350M of­fer­ing; Bio­mX merges with Adap­tive Phage

Last year

Bridge­Bio's $250M of­fer­ing; Vi­iV's PhI da­ta for ul­tra-long-act­ing HIV treat­ment

Last year

FDA push­es back de­ci­sion on Zevra’s drug; Re­vance to raise $100M

Last year

Achieve Life Sci­ences nabs $124M; Pierre Fab­re buys pan-RAF pro­gram from Kin­nate

Last year

Avid­i­ty to raise $400M; Sato pays Ar­cutis $25M up­front to li­cense top­i­cal rof­lu­mi­last in Japan

Last year

Viking's $350M of­fer­ing; Bak­er Broth­ers leads an­oth­er PIPE

Last year

De­nali’s $500M place­ment; Brain health start­up rais­es $26M

Last year

Mile­stone’s plans to re­sub­mit heart drug; Alvotech’s $166M of­fer; Vac­cine biotech rais­es $11M

Last year

Karuna push­es back KarXT da­ta read­outs; Vir, GSK end flu col­lab­o­ra­tion; Si­lence’s $10M mile­stone pay­ment

Last year

MD An­der­son buys tech from Bel­licum; Tar­sus’ Ly­me dis­ease tri­al da­ta; Rigel takes Gavre­to

Last year

New dose sched­ule for J&J bis­pe­cif­ic; Lay­offs at Ring Ther­a­peu­tics; Re­gen­eron’s pri­or­i­ty re­view

Last year
First page Previous page 9101112131415 Next page Last page
A service from the Financial Times